ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 300 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical corticosteroid | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 250 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 260 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
